全文获取类型
收费全文 | 11670篇 |
免费 | 694篇 |
国内免费 | 105篇 |
专业分类
耳鼻咽喉 | 109篇 |
儿科学 | 312篇 |
妇产科学 | 332篇 |
基础医学 | 1489篇 |
口腔科学 | 454篇 |
临床医学 | 918篇 |
内科学 | 2910篇 |
皮肤病学 | 141篇 |
神经病学 | 964篇 |
特种医学 | 465篇 |
外科学 | 1955篇 |
综合类 | 36篇 |
预防医学 | 493篇 |
眼科学 | 121篇 |
药学 | 689篇 |
中国医学 | 33篇 |
肿瘤学 | 1048篇 |
出版年
2024年 | 8篇 |
2023年 | 82篇 |
2022年 | 230篇 |
2021年 | 388篇 |
2020年 | 226篇 |
2019年 | 330篇 |
2018年 | 409篇 |
2017年 | 275篇 |
2016年 | 334篇 |
2015年 | 394篇 |
2014年 | 600篇 |
2013年 | 657篇 |
2012年 | 973篇 |
2011年 | 987篇 |
2010年 | 535篇 |
2009年 | 516篇 |
2008年 | 772篇 |
2007年 | 792篇 |
2006年 | 664篇 |
2005年 | 655篇 |
2004年 | 649篇 |
2003年 | 519篇 |
2002年 | 422篇 |
2001年 | 73篇 |
2000年 | 70篇 |
1999年 | 81篇 |
1998年 | 75篇 |
1997年 | 77篇 |
1996年 | 61篇 |
1995年 | 53篇 |
1994年 | 58篇 |
1993年 | 54篇 |
1992年 | 43篇 |
1991年 | 51篇 |
1990年 | 41篇 |
1989年 | 36篇 |
1988年 | 30篇 |
1987年 | 27篇 |
1986年 | 34篇 |
1985年 | 22篇 |
1984年 | 23篇 |
1983年 | 11篇 |
1982年 | 11篇 |
1981年 | 8篇 |
1979年 | 14篇 |
1975年 | 11篇 |
1974年 | 11篇 |
1973年 | 8篇 |
1969年 | 9篇 |
1966年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
Katiuscha Merath Fabio Bagante Qinyu Chen Eliza W. Beal Ozgur Akgul Jay Idrees Mary Dillhoff Jordan Cloyd Carl Schmidt Timothy M. Pawlik 《Journal of gastrointestinal surgery》2018,22(9):1538-1548
Objective
Decreasing hospital length-of-stay (LOS) may be an effective strategy to reduce costs while also improving outcomes through earlier discharge to the non-hospital setting. The objective of the current study was to define the impact of discharge timing on readmission, mortality, and charges following hepatopancreatobiliary (HPB) surgery.Methods
The Nationwide Readmissions Database (NRD) was used to identify patients undergoing HPB procedures between 2010 and 2014. Length of stay (LOS) was categorized as early discharge (4–5 days), routine discharge (6–9 days), and late discharge (10–14 days). Univariable and multivariable analyses were utilized to identify factors associated with 90-day readmission.Results
A total of 28,114 patients underwent HPB procedures. Overall median LOS was 7 days (IQR 5–11); 10,438 (37.1%) patients had an early discharge, while 13,665 (48.6%) and 4011 (14.3%) patients had a routine or late discharge. The probability of early discharge increased over time (referent 2010: 2011–4% (OR 1.04, 95% CI 0.96–1.15) vs. 2012–10% (OR 1.10, 95% CI 1.01–1.20) vs. 2013–21% (OR 1.21, 95% CI 1.11–1.32) vs. 2014–32% (OR 1.32, 95% CI 1.21–1.44)) (p?<?0.001). Early discharge was associated with insurance status, diagnosis (benign vs. malignant disease), general health, and overall hospital volume (all p?<?0.05). Among patients who had an early discharge, 30- and 90-day readmission was 11.5 and 17.4%, respectively. In contrast, 30- and 90-day readmission was 16.9 and 24.7%, respectively, among patients who had a routine discharge group (p?<?0.001). Among patients readmitted within 90 days, in-hospital mortality was similar among patients who had early (n?=?43, 2.4%) versus routine discharge (n?=?65, 1.9%). Median charges were lower among patients who had an early versus routine versus late discharge ($54,476 [IQR 40,053–79,100] vs. $75,192 [IQR 53,296–113,123] vs. $115,061 [IQR 79,162–171,077], respectively) (p?<?0.001).Conclusions
Early discharge after HPB surgery was not associated with increased 30- or 90-day readmission. Overall 90-day in-hospital mortality following a readmission was comparable among patients with an early, routine, and late discharge, while median charges were lower in the early discharge group.992.
Derosa G Cicero AF Gaddi AV Ciccarelli L Piccinni MN Salvadeo S Pricolo F Fogari E Ghelfi M Ferrari I Fogari R 《Clinical therapeutics》2005,27(9):1383-1391
BACKGROUND: Some evidence suggests that antihyperglycemic drugs might have a small but clinically significant beneficial effect on blood pressure in patients with diabetes mellitus. Based on a literature search, few direct comparisons of different antihyperglycemic treatments on blood pressure have been reported. OBJECTIVES: The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome. Secondary end points were glycemic control and improvement in insulin sensitivity. METHODS: This randomized, double-blind study was conducted at 2 centers in Italy. Patients aged > or =18 years with DM-2 and the metabolic syndrome and poor glycemic control (insulin resistance) with monotherapy with the maximum tolerated dose of an antihyperglycemic agent (eg, a sulfonylurea, metformin) were enrolled. All patients received 12 months of oral treatment with metformin 500 mg TID plus glimepiride 2 mg QD (G + M) or rosiglitazone 4 mg QD (R + M). Blood pressure, heart rate (HR), and body mass index (BMI); plasma levels of fasting and postprandial glucose and insulin (FPG, PPG, FPI, and PPI, respectively) and glycosylated hemoglobin (HbA(1c)); and homeostasis model assessment (HOMA) index were determined at 0 (baseline), 3, 6, 9, and 12 months of treatment. Adverse effects (AEs) were assessed using spontaneous reporting, patient interview, and laboratory analysis. RESULTS: Ninety-nine patients were enrolled in the study; 95 completed it (48 men, 47 women; mean age, 54 years [range, 47-58 years]; G + M, 47 patients; R + M, 48 patients). Four patients did not complete the study due to noncompliance (2 patients in the R + M group), protocol violation (1 patient in the G + M group), and loss to follow-up (1 patient in the G + M group). Mean blood pressure values were not significantly improved in the G + M group at any time point, whereas these values were significantly improved at 12 months in the R + M group. Mean BMI, HbA(1c), FPG, and PPG were significantly decreased from baseline in both groups at 12 months (all, P < or = 0.05). Mean FPI, PPI, and HOMA index were significantly improved at 12 months only in the R + M group (all, P < or = 0.05 vs baseline); these changes were not found in the G + M group. No significant changes in HR were found. Headache and flatulence were reported in both groups (G + M, 2 patients each; R + M, 1 and 2 patients, respectively), but these AEs were mild and transient. In the R + M group, liver enzyme levels were increased to 1.5-fold the upper limit of normal in 3 patients, but were normalized by study end. CONCLUSIONS: In this study in patients with DM-2 and the metabolic syndrome, long-term (12-month) combination treatment with R + M, but not G + M, was associated with a significant improvement in blood pressure control. Improvements in glycemic control and insulin resistance-related parameters were found at 9 months with R + M, compared with 12 months with G + M. Both treatments were well tolerated. 相似文献
993.
Qinyu Chen Katiuscha Merath Griffin Olsen Fabio Bagante Jay J. Idrees Ozgur Akgul Jordan Cloyd Carl Schmidt Mary Dillhoff Eliza W. Beal Susan White Timothy M. Pawlik 《Journal of gastrointestinal surgery》2018,22(7):1221-1229
Background
The relationship between the post-discharge settings and the risk of readmission has not been well examined. We sought to identify the association between discharge destinations and readmission rates after liver and pancreas surgery.Methods
The 2013–2015 Medicare-Provider Analysis and Review (MEDPAR) database was reviewed to identify liver and pancreas surgical patients. Patients were subdivided into three groups based on discharge destination: home/self-care (HSC), home with home health assistance (HHA), and skilled nursing facility (SNF). The association between post-acute settings, readmission rates, and readmission causes was assessed.Results
Among 15,141 liver or pancreas surgical patients, 60% (n?=?9046) were HSC, 26.9% (n?=?4071) were HHA, and 13.4% (n?=?2024) were SNF. Older, female patients and patients with ≥?2 comorbidities, ≥?2 previous admissions, an emergent index admission, an index complication, and ≥?5-day length of stay were more likely to be discharged to HHA or SNF compared to HSC (all P?<?0.001). Compared to HSC, HHA and SNF patients had a 34 and a 67% higher likelihood of 30-day readmission, respectively. The HHA and SNF settings were also associated with a 33 and a 69% higher risk of 90-day readmission. There was no association between discharge destination and readmission causes.Conclusion
Among liver and pancreas surgical patients, HHA and SNF patients had a higher risk of readmission within 30 and 90 days. There was no difference in readmission causes and discharge settings. The association between discharge setting and the higher risk of readmission should be further evaluated as the healthcare system seeks to reduce readmission rates after surgery.994.
The most relevant randomized controlled trials of interferon-alpha (IFN) for naive patients with chronic hepatitis C (CHC) published in a decade, just before appearance of pegylated IFN trials in 2000, were included in this paper. Its purpose is to review the relationship between sustained biochemical response in active versus control group versus usual clinical variables as IFN regimens, cirrhosis, genotype and versus less frequently addressed variables as funding, methodological quality or location of principal author. Meta-analysis estimates of global treatment effect varied according to trial design: group 1=IFN versus placebo/no treatment, 32 RCTs, 2499 pts, OR 9.5 (6.3-14.2); group 2a=comparison of IFN schedules, 43 RCTs, 7454 pts, OR 1.6 (1.4-1.9); group 2b=IFN+other drugs versus standard IFN, 30 RCTs, 4737 pts, OR 2.0 (1.6-2.6). Fixed effects (arm-level) meta-regression on the complete data set (171 arms, 10,580 pts) revealed that sustained response was most likely in experimental arms of IFN+ribavirin or other drugs (OR 2.4), arms using yearly schedule (OR 2.0), trial principal author from Asia (OR 1.7), trial sample size >200 (OR 1.4) and arms enrolling less than 50% of cirrhotics (OR 1.3). Moreover, focus was on some significant interactions too, as the effect of trial's quality interacting to the recorded funding (more benefit if no-profit, less if for-profit) and the effect of trial funding interacting to the location of first author (more benefit if from Asia). Three main effects (experimental arm, cirrhosis, funding) and one interaction (funding*location of principal author) explained 31% of between study variability in a random-effect meta-regression. In a subgroup analysis on a data set including available information on HCV genotype (93 arms, around 7000 pts), meta-regression revealed that genotype 1 or 4 less than 50% per arm and specialistic journal were significant predictors of either biochemical (transaminases) or virological (HCV-RNA) sustained response, in a model including the same main effects identified in the complete data set analysis. Finally, although mostly captured by different IFN regimens along time, heterogeneity of effect in a large set of (not-pegylated) IFN trials was also explained by HCV genotype and variables of quality and reporting, such as trial's principal author from Asia. 相似文献
995.
Pompili M Basso M Grieco A Vecchio FM Gasbarrini G Rapaccini GL 《The Annals of pharmacotherapy》2004,38(11):1844-1847
OBJECTIVE: To describe a case of recurrent acute hepatitis related to the use of cetirizine, a selective histamine(1)-receptor antagonist approved for the treatment of common allergic diseases. CASE SUMMARY: A 26-year-old man was hospitalized with a week-long history of weakness, nausea, anorexia, and hyperchromic urine, which had developed after 6 days of therapy with oral cetirizine 10 mg/day for allergic rhinitis. Admission laboratory testing revealed evidence of acute hepatitis and seropositivity for liver-kidney microsome antibodies. Liver biopsy findings of diffuse portal tract and lobular inflammation with a prominent eosinophilic infiltrate were consistent with drug-related hepatitis. The patient was discharged after one week of treatment with tocopherol and glutathione. Three months after discharge, transaminase levels were normal. At 6 months, seropositivity for liver-kidney microsome antibodies was still present, but considerably less intense. The patient had suffered 2 previous episodes of "acute hepatitis of unknown origin," and both had occurred after cetirizine use. DISCUSSION: Use of the Naranjo probability scale indicated cetirizine as the probable cause of acute hepatitis, and the positivity for liver-kidney microsome antibodies is suggestive of an autoimmune mechanism for liver damage. As of September 13, 2004, ours is the fourth reported case of acute hepatitis associated with cetirizine and the second in which liver-kidney microsome antibodies have been documented. CONCLUSIONS: Although cetirizine is considered to have low potential for severe hepatic toxicity, the possibility that it can provoke autoimmune-mediated hepatotoxicity should be considered. 相似文献
996.
Gaiani S Serra C Piscaglia F Celli N Rasciti L Miglioli M Bolondi L 《Ultrasound in medicine & biology》2003,29(5):643-648
This study was aimed to assess the effect of Levovist on Doppler parameters of splanchnic hemodynamics. A total of 12 patients with cirrhosis and 12 healthy subjects underwent Doppler ultrasound (US) examination of the portal vein and of the hepatic, splenic and superior mesenteric arteries before, 5 to 8 and 12 to 15 min after the start of an 8-min long IV infusion of 2.5 g of Levovist. Mean velocity and mean diameter were calculated for the portal vein. Resistance index was determined for the arteries. A significant increase of resistance index was observed in the hepatic (0.80 +/- 0.07 vs. 0.71 +/- 0.06; p < 0.01) and splenic arteries (0.72 +/- 0.06 vs. 0.64 +/- 0.06; p < 0.01) 5 to 8 min after contrast agent injection in patients with cirrhosis, but not in controls. Neither portal vein diameter nor portal flow mean velocity changed during the test in both controls and cirrhotic patients. This effect might be related to a selective trapping of microbubbles in the altered hepatic and splenic microvasculature in patients with cirrhosis rather than being artefactual. It might have implications on harmonic imaging US protocols designed to image the cirrhotic liver in the early arterial phase. 相似文献
997.
998.
Dr. Mario Pirisi Alessandro Cavarape Carlo Fabris Cathryn Scott Edmondo Falleti Edda Federico Gianfranco Rizzuti Fabio Gonano Carlo Alberto Beltrami Ettore Bartoli 《Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie》1996,196(1):309-315
Recently, endotoxaemia has been reported as a prognostic marker in acute pancreatitis. However, the role of endotoxin in inducing or aggravating acute pancreatitis is not fully understood. We administered endotoxin 400 μg/kg i.p. to rats 24 h before performing either a closed duodenal loop (group B) or a sham operation (group D). Pancreatic damage and overall survival were compared with the results obtained in rats not exposed to endotoxin undergoing either closed duodenal loop (group A) or sham treatment (group C). In a first set of experiments, 24 h after laparotomy blood samples were collected and the animals were sacrificed; survival up to 8 days was estimated in a second set of experiments. Group B had higher lipase concentrations and more severe tissue damage than group C (P<0.05). A larger number of abscesses was observed in both group B and group D as compared to group C (P<0.05). Survival was significantly shorter in group B (P<0.0001). We conclude that priming with endotoxin worsens the extent of pancreatic damage induced by the closed duodenal loop procedure in the rat, possibly favouring selective homing of neutrophils to the site of inflammation, in similarity to what happens in the Shwartzman phenomenon. 相似文献
999.
Francesco Lanza Luisa Ferrari Laura Sighinolfi Florio Ghinelli Angela Latorraca Sabrina Moretti Lucio Trevisani Alfredo Potena Fabio Malavasi Gianluigi Castoldi 《International Journal of Clinical & Laboratory Research》1993,23(1-4):146-150
Summary In this study we evaluated the phenotype of alveolar mononuclear phagocytes recovered from the bronchoalveolar lavage fluid
of 24 patients with human immunodeficiency virus infection (AIDS-related complex 8 patients, AIDS 16 patients) and 8 healthy
individuals by using a panel of monoclonal antibodies known to react with tissue macrophages, in combination with a flow cytometer.
The results showed that 90% of patients with AIDS present a marked reduction in the expression of several antigenic determinants
(in descreasing order: CD68, CD36, CR1, CD11c, HLA-DR). The levels of antigen expression by flow cytometry seem to decline
with disease progression, showing the most dramatic perturbations in patients with full-blown AIDS associated with pulmonary
infections (especiallyPneumocystis carinii pneumonia) and lower peripheral CD4 lymphocyte counts. In contrast, patients with AIDS-related complex or AIDS without histological
or cultural evidence of pulmonary involvement showed, respectively, only minimal or medium antigenic decreases. However, only
a minor proportion (16%, 20%, 20%, 25%, and 25% respectively) of human immunodeficiency virus infected patients (mostly with
AIDS) had a significant reduction of the levels of CD4, CD14, CD45R, CD11b, and CD16 antigens in the alveolar macrophages.
Since macrophages play a central role in the pathogenesis of AIDS, it may be postulated that the loss of various phenotypic
markers on alveolar mononuclear phagocytes (some of them known for their important immunoregulatory actions) could have an
important part in the pathogenesis of human immunodeficiency virus induced immunosuppression, and thereby condition the abnormal
susceptibility to pulmonary diseases typical of human immunodeficiency virus-infected patients. 相似文献
1000.
Brakebusch C Bouvard D Stanchi F Sakai T Fässler R 《The Journal of clinical investigation》2002,109(8):999-1006